About: Effects of specific egg yolk immunoglobulin on pan-drug-resistant Acinetobacter baumannii

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of specific egg yolk immunoglobulin on pan-drug-resistant Acinetobacter baumannii Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of specific egg yolk immunoglobulin on pan-drug-resistant Acinetobacter baumannii
Creator	Du, Linying Long, Yayi Shi, Huaying Shi, Lei Sun, Lidan Wang, Huaxin Xu, Hong Zhen, Yuhong Zhu, Jie Zou, Boyang
Source	Elsevier; Medline; PMC
abstract	Abstract With the growing emergence of pan-drug-resistant Acinetobacter baumannii (PDR-Ab) strains in clinical, new strategies for the treatment of PDR-Ab infections are urgently needed. Egg yolk immunoglobulin (IgY) as a convenient and inexpensive antibody has been widely applied to the therapy of infectious diseases. The aim of this study was to produce IgY specific to PDR-Ab and investigate its antibacterial effects in vitro and in vivo. IgYs specific to two PDR-Ab strains were produced by immunizing hens with formaldehyde inactivated PDR-Ab cells and isolated from yolks with a purity of 90% by water dilution, salt precipitations and ultrafiltration. IgYs showed high titers when subjected to an ELISA and inhibited the growth of PDR-Ab in a dose-dependent manner in liquid medium. Scanning electron microscopy assay showed structural modification and aggregation of PDR-Ab treated with specific IgYs. Freshly cultured PDR-Ab cells were nasally inhaled in BALB/c mice to induce acute pneumonia. The infected mice were intraperitoneally injected with specific IgYs using cefoperazone/sulbactam and dexamethasone as positive controls. The IgYs specific to PDR-Ab lowered the mortality of mice with PDR-Ab-induced acute pneumonia, decreased the level of TNF-α and IL-1β in serum and reduced inflammation in lung tissue. Specific IgY has the potential to be used as a new therapeutic approach for the treatment of A. baumannii-induced infections.
has issue date	2017-11-30(xsd:dateTime)
bibo:doi	10.1016/j.biopha.2017.09.112
bibo:pmid	28962078
has license	els-covid
sha1sum (hex)	a2e23dac907018e5311d7a8aff1b778a85265af6
schema:url	https://doi.org/10.1016/j.biopha.2017.09.112
resource representing a document's title	Effects of specific egg yolk immunoglobulin on pan-drug-resistant Acinetobacter baumannii
has PubMed Central identifier	PMC7126593
has PubMed identifier	28962078
schema:publication	Biomedicine & Pharmacotherapy
resource representing a document's body	covid:a2e23dac907018e5311d7a8aff1b778a85265af6#body_text
is schema:about of	named entity 'IMMUNOGLOBULIN' named entity 'INDUCED INFECTIONS' named entity 'MORTALITY' named entity 'LUNG TISSUE' named entity 'PDR' named entity 'DRUG' named entity 'TREATED WITH' named entity 'HIGH' named entity 'INDUCE' named entity 'USING' named entity 'INFLAMMATION' named entity 'LOWERED' named entity 'INFECTED' named entity 'TREATMENT' named entity 'SCANNING ELECTRON MICROSCOPY' named entity 'ANTIBACTERIAL' named entity 'ULTRAFILTRATION' named entity 'INACTIVATED' named entity '90%' named entity 'INVESTIGATE' named entity 'EFFECTS' named entity 'dose-dependent' named entity 'reduced' named entity 'therapy' named entity 'IgY' named entity 'induce' named entity 'growing' named entity 'IL-1β' named entity 'EGG YOLK' named entity 'IMMUNOGLOBULIN' named entity 'REDUCED' named entity 'EFFECTS' named entity 'DRUG' named entity 'SPECIFIC' named entity 'STUDY' named entity 'RESISTANT' named entity 'THERAPY' named entity 'NEEDED' named entity 'SALT' named entity 'AB CELLS' named entity 'STRAINS' named entity 'POSITIVE' named entity 'ACINETOBACTER BAUMANNII' named entity 'TO PRODUCE' named entity 'LIQUID MEDIUM' named entity 'STRUCTURAL MODIFICATION' named entity 'WATER' named entity 'FORMALDEHYDE' named entity 'INFECTIONS' named entity 'CLINICAL' named entity 'IL-1' named entity 'LEVEL' named entity 'IN VIVO' named entity 'NEW' named entity 'APPROACH' named entity 'BALB' named entity 'APPLIED' named entity 'RESISTANT' named entity 'ACINETOBACTER BAUMANNII' named entity 'PAN' named entity 'ISOLATED' named entity 'HENS' named entity 'THERAPEUTIC' named entity 'STRATEGIES' named entity 'ACUTE PNEUMONIA' named entity 'CEFOPERAZONE' named entity 'PURITY' named entity 'SPECIFIC' named entity 'INHALED' named entity 'MICE' named entity 'MICROSCOPY ASSAY' named entity 'EGG YOLK'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software